Alkermes plc buy melinda
Start price
19.06.17
/
50%
€51.55
Target price
05.07.17
€54.12
Performance (%)
5.28%
End price
05.07.17
€54.27
Summary
This prediction ended on 05.07.17 with a price of €54.27. The BUY prediction by melinda finished with a performance of 5.28%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alkermes plc | -4.412% | -4.412% | -20.732% | 1.941% |
| iShares Core DAX® | 1.232% | 1.501% | 11.288% | 63.495% |
| iShares Nasdaq 100 | 0.695% | -1.949% | 5.586% | 88.830% |
| iShares Nikkei 225® | 2.085% | 11.061% | 31.150% | 67.951% |
| iShares S&P 500 | 0.419% | 0.215% | 4.116% | 60.991% |
Comments by melinda for this prediction
In the thread Alkermes plc diskutieren
genehmigt (FDA)
Die US Food and Drug Administration (FDA) genehmigt hat ALKERMES des zweimonatigen Aristada (Aripiprazol lauroxil) extended-release injizierbare Suspension zur Behandlung von Schizophrenie.